About Totient
Totient is a company based in Cambridge (United States) founded in 2017 by James Sietstra and Deniz Kural was acquired by AbSci in June 2021. Totient has raised $10.5 million across 3 funding rounds from investors including AbSci, Viva Biotech and Viva BioInnovator. The company has 26 employees as of December 31, 2022. Totient operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 26 as on 31 Dec, 2022
- Founders James Sietstra, Deniz Kural
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sbgd, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Totient
Unlock access to complete
Unlock access to complete
Funding Insights of Totient
Totient has successfully raised a total of $10.5M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Totient
Totient has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include AbSci, Viva Biotech and Viva BioInnovator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech companies in Asia and the US are funded.
|
Locked | Locked | Locked | |
|
Seed-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Kaitai Capital is engaged in innovation investment management services.
|
Locked | Locked | Locked |
Investor details for Totient
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Totient
Investment portfolio details for Totient
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Totient
Detailed financials for Totient
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Totient Comparisons
Peer comparison for Totient
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Totient
Totient operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Totient
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Totient
Complete news archive for Totient
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Totient
Totient was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Totient is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Deniz Kural is the current CEO of Totient. They have also founded this company.
Totient is a funded company, having raised a total of $10.5M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Totient is 26.
Developer of a drug discovery platform for cancer and autoimmune disease using artificial intelligence. The company uses immunoinformatics-algorithms, machine learning techniques, and tertiary lymphoid structures (TLS) for the identification of novel tissue-specific antigens and antibodies expressed by the cancer-affected tissues. The company develops cancer therapeutics by reconstructing antibodies from tissues affected by autoimmunity, infections, and cancer. The company has developed antibodies against novel extracellular oncology targets that include GAGE1, GAGE2A, LIVIN (BIRC7), PCNA, ANXA1, C4BPB, HCLS1, GPR83, and IL14A.
Totient's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
Totient has 9 investors. Key investors include AbSci, Viva Biotech, Viva BioInnovator, CerraCap Ventures, and Tau Ventures.